Monte Rosa Therapeutics (GLUE) Assets Average: 2023-2025
Historic Assets Average for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $409.7 million.
- Monte Rosa Therapeutics' Assets Average rose 24.31% to $409.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $409.7 million, marking a year-over-year increase of 24.31%. This contributed to the annual value of $371.2 million for FY2024, which is N/A change from last year.
- Per Monte Rosa Therapeutics' latest filing, its Assets Average stood at $409.7 million for Q3 2025, which was up 8.85% from $376.4 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Assets Average peaked at $416.0 million during Q1 2025, and registered a low of $265.4 million during Q3 2023.
- In the last 3 years, Monte Rosa Therapeutics' Assets Average had a median value of $317.5 million in 2024 and averaged $333.6 million.
- Data for Monte Rosa Therapeutics' Assets Average shows a peak YoY surged of 45.82% (in 2025) over the last 5 years.
- Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Assets Average stood at $277.9 million in 2023, then surged by 35.61% to $376.9 million in 2024, then rose by 24.31% to $409.7 million in 2025.
- Its last three reported values are $409.7 million in Q3 2025, $376.4 million for Q2 2025, and $416.0 million during Q1 2025.